Back to all Programs

Register here

Related Materials

Past event

International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2018

How studies can be optimized by simultaneous use of PK/PD outcome measurement? | Alwin Huitema

The value of surrogate endpoints in the benefit-risk assessment of new drugs | Gabe Sonke, MD, PhD

Clinical relevance of liquid biopsy in cancer patients | Catherine Alix-Panabières, PhD

Drug-Drug interactions with targeted oncolytics (in particular PPIs and TKIs) | Ron Mathijssen

Pharmacotherapy of Comorbities: Cancer Patients with HIV/AIDS | Michelle Rudek, PharmD, PhD

Drug-drug interaction management with DDI-Predictor | Michel Tod, PharmD, PhD

Immunotherapy of prostate cancer and urothelial cancer. Future directions | Winald Gerritsen

Rationale for selecting combinations with immunotherapy | Howard Gurney, MBBS, FRACP

Cytotoxic agents | Markus Jörger, MD, PhD

Targeted agents and monoclonal antibodies | Joseph Ciccolini, PharmD, PhD